About us

We are on a mission to make a meaningful impact on the lives of patients with blood-related cancers.
At CTI, we are resolute in our commitment to deliver new medicines to patients with blood-related cancers who have limited treatment options. With our deep hematology-oncology expertise and sense of urgency, we are motivated to shift the treatment paradigm for blood-related cancers.

By identifying specific patient communities currently underserved by existing therapies and uncovering the scientific factors driving their diseases, we aim to advance the development of therapies that are potentially less toxic and more effective at treating patients.

We are focused on the acquisition, development and commercialization of novel therapies for blood-related cancers where there is significant unmet need.

At CTI, we are all deeply connected to each other and our work, united in our quest to improve the lives of patients and their families facing blood-related cancers. Our team holds diverse expertise advancing hematology, oncology and rare disease therapies for patients worldwide, and shares one vision for transforming the future of cancer treatment through scientific excellence and compassion.